CHEMOTHERAPY OF LOCALISED HISTIOCYTIC LYMPHOMA

Thomas P. Miller; Stephen E. Jones

doi:10.1016/S0140-6736(79)92894-0

CHEMOTHERAPY OF LOCALISED HISTIOCYTIC LYMPHOMA

Thomas P. Miller, Stephen E. Jones

English

Research output: Contribution to journal › Article › peer-review

57 Scopus citations

Abstract

22 patients with localised (stage I or II) diffuse lymphoma were treated with chemotherapy at the time of diagnosis. 14 patients received chemotherapy as the only treatment, and 8 received chemotherapy plus local irradiation. Doxorubicin-containing drug regimens were used in 20 patients. All 22 patients achieved a complete remission and remain alive with a median survival from the time of diagnosis of 27+ months. 21 patients (95%) have remained continuously free of disease with a median disease-free survival from the completion of chemotherapy of 23+ months. These findings provide a strong rationale for further clinical trials of chemotherapy alone or chemotherapy followed by regional radiotherapy for localised stages of diffuse lymphoma.

Original language	English (US)
Pages (from-to)	358-360
Number of pages	3
Journal	The Lancet
Volume	313
Issue number	8112
DOIs	https://doi.org/10.1016/S0140-6736(79)92894-0
State	Published - Feb 17 1979

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/S0140-6736(79)92894-0

Cite this

@article{cfdd95c2dbdf4aedb9a852fcffe2fdd8,

title = "CHEMOTHERAPY OF LOCALISED HISTIOCYTIC LYMPHOMA",

abstract = "22 patients with localised (stage I or II) diffuse lymphoma were treated with chemotherapy at the time of diagnosis. 14 patients received chemotherapy as the only treatment, and 8 received chemotherapy plus local irradiation. Doxorubicin-containing drug regimens were used in 20 patients. All 22 patients achieved a complete remission and remain alive with a median survival from the time of diagnosis of 27+ months. 21 patients (95%) have remained continuously free of disease with a median disease-free survival from the completion of chemotherapy of 23+ months. These findings provide a strong rationale for further clinical trials of chemotherapy alone or chemotherapy followed by regional radiotherapy for localised stages of diffuse lymphoma.",

author = "Miller, {Thomas P.} and Jones, {Stephen E.}",

year = "1979",

month = feb,

day = "17",

doi = "10.1016/S0140-6736(79)92894-0",

language = "English (US)",

volume = "313",

pages = "358--360",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "8112",

}

TY - JOUR

T1 - CHEMOTHERAPY OF LOCALISED HISTIOCYTIC LYMPHOMA

AU - Miller, Thomas P.

AU - Jones, Stephen E.

PY - 1979/2/17

Y1 - 1979/2/17

N2 - 22 patients with localised (stage I or II) diffuse lymphoma were treated with chemotherapy at the time of diagnosis. 14 patients received chemotherapy as the only treatment, and 8 received chemotherapy plus local irradiation. Doxorubicin-containing drug regimens were used in 20 patients. All 22 patients achieved a complete remission and remain alive with a median survival from the time of diagnosis of 27+ months. 21 patients (95%) have remained continuously free of disease with a median disease-free survival from the completion of chemotherapy of 23+ months. These findings provide a strong rationale for further clinical trials of chemotherapy alone or chemotherapy followed by regional radiotherapy for localised stages of diffuse lymphoma.

AB - 22 patients with localised (stage I or II) diffuse lymphoma were treated with chemotherapy at the time of diagnosis. 14 patients received chemotherapy as the only treatment, and 8 received chemotherapy plus local irradiation. Doxorubicin-containing drug regimens were used in 20 patients. All 22 patients achieved a complete remission and remain alive with a median survival from the time of diagnosis of 27+ months. 21 patients (95%) have remained continuously free of disease with a median disease-free survival from the completion of chemotherapy of 23+ months. These findings provide a strong rationale for further clinical trials of chemotherapy alone or chemotherapy followed by regional radiotherapy for localised stages of diffuse lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=0018744047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018744047&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(79)92894-0

DO - 10.1016/S0140-6736(79)92894-0

M3 - Article

C2 - 85006

AN - SCOPUS:0018744047

SN - 0140-6736

VL - 313

SP - 358

EP - 360

JO - The Lancet

JF - The Lancet

IS - 8112

ER -

CHEMOTHERAPY OF LOCALISED HISTIOCYTIC LYMPHOMA

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this